Nasopharyngeal Carcinoma Clinical Trial
Official title:
Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases
Patients have a type of a lymph node cancer called lymphoma, a tumor of the nasal passages
called nasopharyngeal carcinoma (NPC), a tumor of a particular type of muscle called
leiomyosarcoma (LMS) or a condition called severe chronic active EBV (SCAEBV) syndrome. The
disease has come back, may come back or has not gone away after treatment. This voluntary
research study uses special immune system cells called LMP-specific cytotoxic T lymphocytes,
a new experimental therapy.
Some patients with these diseases show evidence of infection with the virus that causes
infectious mononucleosis (called Epstein-Barr virus, or EBV) before or at the time of their
diagnosis. EBV is found in the cancer cells of up to half of the patients with lymphomas, and
in some cases of NPC and LMS, suggesting that it may play a role in causing these diseases.
Those cancer cells (as well as some B cells in SCAEBV) that are infected by EBV are able to
hide from the body's immune system and escape destruction. We want to see if special white
blood cells, called T cells, that have been trained to kill cells infected by EBV can survive
in the blood and affect the tumor.
This treatment with specially trained T cells has had activity against these viruses when the
cells are made from patients with those diseases (or, after bone marrow transplant, from the
patient's transplant donor). However, sometimes it is not possible to grow these cells; other
times, it may take 2 to 3 months to make the cells, which may be too long when one has an
active tumor. We are therefore asking if subjects would like to participate in this study,
which tests if blood cells from a donor that is a partial match with the subject (or the
transplant donor) that have been grown in the way described above can survive in the blood
and affect the disease.
These LMP-specific CTLs are an investigational product not approved by the Food and Drug
Administration.
First, we will search our cell bank to see if there is a CTL line that is a match with the
subject and his/her donor. This matching is done using HLA type, which measures 6 proteins on
the cell surface. If HLA type has not been previously checked, we will do a blood draw (half
to one tablespoon) so that this can be done.
These CTL lines have been made at Baylor College of Medicine from donors for other transplant
patients or other normal donors from the National Marrow Donor Program. All donors have been
screened in the same way that we screen blood donors. When the CTL lines were made, blood was
taken from the donors and used to grow T cells. To do this, we first grew a special type of
cells called dendritic cells or monocytes and we put a specially produced human virus
(adenovirus) that carries the LMP genes into the dendritic cells or monocytes. They were then
used to stimulate T cells. This stimulation trained the T cells to kill cells with LMP on
their surface.
We then grew these LMP specific CTLs by more stimulation with EBV infected cells (made from
the same blood). We also put the adenovirus that carries the LMP genes into these EBV
infected cells so that we increased the amount of LMP that these cells had. These EBV
infected cells were treated with radiation so they could not grow. Once we made sufficient
numbers of T cells, we tested them to make sure they kill cells with LMP on their surface and
froze them.
To make sure that these cells won't attack the subject's tissues, we will also test the cells
against his/her own cells, which we will grow in the laboratory.
If the level of circulating T-cells in the patient is relatively high, s/he will receive one
treatment of cyclophosphamide. This drug will decrease the numbers of the patient's own
T-cells before the investigators infuse the LMP-specific cytotoxic T-lymphocytes. If the
patient is already receiving chemotherapy, this may not be needed.
The LMP specific CTLs will be thawed and injected IV over 1-10 minutes. Initially, one dose
of T-cells will be given. If after the first dose, there is a reduction in the size of the
patient's disease, they can receive up to five additional doses of the T-cells if they wish.
This is a dose escalation study, which means that the doses of cells will be increased as
more patients are treated, as long as the lower doses are determined to be safe.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979961 -
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT06055816 -
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05547971 -
Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
|
||
Not yet recruiting |
NCT05020925 -
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04547088 -
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04548271 -
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT02795169 -
Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02569788 -
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02801487 -
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT02237924 -
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT02044562 -
Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
|
N/A | |
Terminated |
NCT01694576 -
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
|
Phase 2 | |
Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Completed |
NCT01271439 -
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT00535795 -
Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA
|
Phase 3 | |
Completed |
NCT00379262 -
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT03398980 -
Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy
|
N/A | |
Completed |
NCT01309633 -
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
|
Phase 2 |